Bluebird bio lays off staffers in Europe as Zynteglo rollout hits an early reimbursement snag

Bluebird bio lays off staffers in Europe as Zynteglo rollout hits an early reimbursement snag

Source: 
Fierce Pharma
snippet: 

The rollout of bluebird bio’s blood disease gene therapy Zynteglo is off to a rough start—to say the least.

After resolving a manufacturing-related setback and overcoming another delay caused by COVID-19, the Massachusetts biotech has failed to reach a reimbursement deal with authorities in Germany, its first launch country, the company said Tuesday.